Depomed Fights Generic Threat To Glumetza

Law360, New York (June 21, 2011, 1:30 PM EDT) -- Specialty pharmaceutical company Depomed Inc. said Tuesday it had filed a patent lawsuit in New Jersey against Sun Pharmaceutical Industries Inc. over the generics maker's bid to produce its own version of diabetes drug Glumetza.

Menlo Park, Calif.-based Depomed said the lawsuit came in response to Sun filing an abbreviated new drug application with the U.S. Food and Drug Administration seeking permission to market generic versions of the 500- and 1,000-milligram strengths of Glumetza prior to the expiration of five U.S. patents owned by Depomed covering...
To view the full article, register now.